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Context: Neonatal sepsis is associated with prolonged hospital stay and increased 
morbidity and mortality despite appropriate antimicrobial therapy. There are discordant 
results in the existing literature regarding the association between adjunctive 
pentoxifylline therapy and duration of stay or mortality. 
Hypothesis: We hypothesize that among preterm infants with blood culture-confirmed 
sepsis who are treated with pentoxifylline plus appropriate antimicrobial therapy, as 
compared to infants treated with placebo plus appropriate antimicrobial therapy, median 
duration of stay in the neonatal intensive care unit will be significantly reduced. 
Methods: We propose a multicenter, double-blind, placebo-controlled, parallel-group 
randomized controlled trial to investigate the efficacy of adjunctive pentoxifylline 
therapy to reduce duration of stay in the neonatal intensive care unit. 
Significance: Results from this study may identify an agent that can be added to 
antimicrobial therapy to reduce duration of stay and attenuate the associated morbidity, 
mortality, and socioeconomic and emotional burdens of neonatal sepsis. 
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Chapter 1: Introduction 
Background 
Scope of the Problem 
 
 Approximately 4 million infants worldwide die within the first 4 weeks of life 
each year, with infections (35%), preterm birth (28%), and asphyxia (23%) as the leading 
causes of death.1 Bacterial sepsis of the newborn was the seventh leading cause of death 
in the United States in 2011, responsible for 526 of 23 907 reported deaths (2.2%).2 The 
incidence of neonatal sepsis ranges from 1 to 4 cases per 1000 live births to 6.5 to 38 
cases per 1000 live births in the developed and developing world, respectively.3 Some 
investigators have reported a declining mortality rate from newborn sepsis in recent 
years.2,4 Notably, other investigators have reported a continuing disease burden with 
associated mortality,5 as well as a predominance of virulent pathogens and high sepsis-
associated mortality.6 
Regardless of the true overarching association between neonatal sepsis and 
mortality, morbidity remains a significant problem. A recently published meta-analysis 
summarized and analyzed results from 12 studies published between 2000 through 2012 
that enrolled a total of 3669 infants of gestational age < 34 weeks and/or birth weight ≤ 
1500 grams with sepsis and compared them to a control group of 24 723 infants without 
sepsis.4 There was a significant association between neonatal sepsis and short-term 
morbidities, including mortality, respiratory distress syndrome, intraventricular 
hemorrhage (IVH), meningitis, periventricular leukomalacia, and multiple organ failure. 
There was also a significant association between neonatal sepsis and long-term 
morbidities, including death after discharge, bronchopulmonary dysplasia (BPD), 
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cerebral palsy, cognitive delay, psychomotor delay, visual impairment, and auditory 
impairment.4 
In addition to morbidity and mortality, neonatal sepsis and the associated neonatal 
intensive care unit (NICU) stay exert emotional and socioeconomic burdens on infants, 
parents, families, clinicians, the healthcare system, and society.7-14 Parents of an infant 
being cared for in the NICU often experience stress, feel helpless, and struggle to interact 
with their child in a developmentally sensitive manner.8 Among very low-birth-weight 
(VLBW) infants, prolonged hospital stay has been shown to influence parent-infant 
relationships, failure to thrive, child abuse and/or abandonment, and grieving parents.15 
Compounding this burden, NICU costs of care increase by approximately $16 800 when 
comparing VLBW infants with NICU-associated bloodstream infection to similar infants 
without bloodstream infection.16 Neonatal sepsis is associated with longer duration of 
hospitalization.10,17-19 As prolonged hospital stay is also associated with nosocomial 
infection16 and increased exposure to other hospital-acquired morbidities,20 this may 
potentially exacerbate emotional and socioeconomic strains. In fact, the duration of an 
infant’s initial hospitalization is predictive of his or her long-term medical resource 
requirements.18 
Definitions 
While sepsis is a well-known clinical entity, specific definitions of sepsis and 
related terminology vary in the literature. That “sepsis” is nebulous is understandable 
considering the sepsis continuum, which spans systemic inflammatory response 
syndrome, infection, sepsis, severe sepsis, septic shock, and organ dysfunction,21 as well 
as additional related terms, including bacteremia, septicemia, septic syndrome, sepsis-
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induced hypotension, and multiple organ dysfunction syndrome.22 The term “clinical 
sepsis,” defined as physician-diagnosed sepsis without blood culture confirmation,23 is 
not universally applied in the literature. For clarification, clinical signs and hematologic 
criteria have been proposed and validated for the neonatal population (see Appendix A).24 
Validated criteria are crucial in this vulnerable population in which sepsis presents 
variably and non-specifically.14,19,24 In the aforementioned validation study, at least 2 
clinical criteria and at least 1 hematologic criterion incited a sepsis evaluation.24 
Ultimately, the attending neonatologist uses his or her expert clinical judgment to 
determine when to evaluate an infant for sepsis.25 
Neonatal sepsis is most commonly defined based upon timing of disease onset. 
Early-onset sepsis is defined as laboratory-confirmed bloodstream infection at ≤ 72 hours 
of life, while late-onset sepsis is defined as laboratory-confirmed bloodstream infection at 
> 72 hours of life.6,24-26 Risk factors for early-onset sepsis include maternal group B 
Streptococcus colonization, maternal chorioamnionitis, premature rupture of amniotic 
membranes, prolonged rupture of amniotic membranes (> 18 hours from membrane 
rupture to delivery), and multiparity.25,27,28 Risk factors for late-onset sepsis include 
delivery by cesarean section, the use of indwelling vascular catheters, invasive 
procedures, prolonged mechanical ventilation, prolonged antibiotic administration, 
hyperalimentation, and comorbidities such as patent ductus arteriosus, necrotizing 
enterocolitis (NEC), and BPD.25,26,28 Prematurity3,25-27 and its frequently associated lower 
birth weight3,26,27,29 are risk factors for both early-onset3,27,29 and late-onset sepsis.3,25-27,29  
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Microbiology 
Just as the semantics of sepsis are dynamic, so too are the isolated microbiological 
flora. Yale-New Haven Hospital’s (YNHH) single-center longitudinal database of 
neonatal bloodstream infections allows for analysis of the changing microbiological 
landscape of neonatal sepsis. During the 15-year period from 1989 through 2003, of 755 
episodes of sepsis, the most common organisms isolated from blood culture were 
coagulase-negative staphylococci (29%), Escherichia coli (12%), group B Streptococcus 
(10%), and Staphylococcus aureus (8%).30 Comparing these results to the previous 60 
years, observed trends included: (1) a significant decline in Streptococcus pneumoniae 
and Streptococcus pyogenes, with no episodes of resultant sepsis reported from 1989 
through 2003; (2) a decline in group B streptococci; (3) a decline in E coli; and (4) an 
increase in commensal species, including coagulase-negative staphylococci, S aureus, 
and Candida species.30 
More recently at YNHH, of 410 episodes of sepsis during the 10-year period from 
2004 through 2013, the most common organisms isolated from blood culture were 
coagulase-negative staphylococci (29%), S aureus (16%), E coli (14%), and 
Enterococcus faecalis (12%).6 Notable trends during this 10-year study period included: 
(1) a static rate of group B streptococci, (2) the emergence of E coli as the most common 
etiology of early-onset sepsis, and (3) a decline in coagulase-negative staphylococci as an 
etiology of late-onset sepsis in conjunction with NICU-wide infection prevention 
initiatives implemented in 2008 and 2009.6 
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Pathophysiology 
 The transition from intrauterine to extrauterine life is a hazardous time for infants. 
Many vehicles, such as the uterus, birth canal, neonatal care unit, invasive procedures and 
devices, healthcare providers, family, visitors, and the community, can transmit virulent 
microorganisms.27 In addition to multiple exposures, VLBW and premature infants are 
vulnerable to sepsis due to relative immunocompromise.24,27 Despite myriad research 
over decades, the exact mechanisms of sepsis remain elusive.31 The most basic premise 
appears dogmatic: sepsis occurs when pathogens invade the body and the ensuing 
inflammatory response becomes systemic and affects tissues and organ systems at distant 
sites from the initial infection.31 The inflammatory response was initially presumed to be 
solely pro-inflammatory, with cytokines such as tumor necrosis factor (TNF), interleukin 
(IL)-1, interleukin (IL)-6, and interferon (IFN)-γ playing integral roles. Later hypotheses 
articulated a subsequent, compensatory anti-inflammatory response with a predominance 
of IL-10, IL-1 receptor antagonist, and TNF-soluble receptors.31 More recent hypotheses 
support concomitantly produced pro- and anti-inflammatory cytokines that elicit a mixed 
anti-inflammatory response. No matter the balance between inflammation and 
immunosuppression, studies employing mathematical modeling of response to sepsis 
emphasize the necessity and benefit of some degree of inflammation.31 
Diagnosis and Routine Care 
Accurate and timely diagnosis is the first step to ameliorate the morbidity and 
mortality associated with neonatal sepsis.19 Peripheral blood culture is the current gold 
standard of diagnosis.25,32,33 Since sepsis is often recognized only when infants begin to 
clinically deteriorate, blood cultures are obtained for infants with maternal risk factors for 
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neonatal sepsis as well as for infants with symptoms that suggest infection34,35 (see 
Appendix A). Routine care is supportive care focused on ensuring adequate systemic 
oxygenation and peripheral perfusion19 in addition to empirical treatment with parenteral 
broad-spectrum antimicrobials for 48 to 72 hours while blood culture results are 
pending.19,25,34 Once sepsis is confirmed by blood culture antimicrobial treatment is 
tailored to the sensitivity pattern of the isolated microorganism.19,36,37  
Adjunctive Therapy 
Adjunctive therapies for neonatal sepsis mimic the trends in pathophysiological 
understanding: some attenuate while others augment the immunoinflammatory system. 
Of many adjunctive therapies investigated among the neonatal population with cohort 
studies, randomized clinical trials (RCTs), and systematic reviews, those associated with 
a significant reduction in sepsis or mortality include exchange transfusion, pentoxifylline, 
selenium, lactoferrin, probiotics, breast milk, and polyclonal intravenous 
immunoglobulin.38 Adjunctive therapies not shown to significantly reduce sepsis or 
mortality include granulocyte transfusion, granulocyte- and granulocyte-monocyte colony 
stimulating factor, activated protein C, melatonin, glutamine, prebiotics, broad-spectrum 
peripartum antibiotics, immunoglobulin M-enriched intravenous immunoglobulin, 
monoclonal intravenous immunoglobulin, and antiendotoxin antibodies.38,39 
Pentoxifylline 
Investigation of pentoxifylline (PTX; 1-[5-oxohexyl]-3,7-dimethylxanthine)40 for 
neonatal sepsis began in the 1990s.41 Pentoxifylline is a promising adjunctive therapy 
because it has been shown to modulate the immune response by inhibiting 
phosphodiesterase enzyme.36 This inhibition in turn activates adenylyl cyclase, increases 
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cyclic AMP concentrations, and suppresses pro-inflammatory cytokines such as TNF-
α,3,10,38 IL-1,3,38 IL-6,10 and IFN-γ.10 Interestingly, increased concentration of TNF-α is 
associated with mortality in sepsis.3,36,42,43 Tumor necrosis factor-α3,10 and platelet 
activating factor3 have also been implicated in neonates with NEC. Pentoxifylline has 
beneficial effects for the cardiovascular system, including decreasing superfluous 
coagulation, lowering blood viscosity, preventing the hypodynamic state that often 
accompanies sepsis, improving endothelial cell function, increasing tissue perfusion, and 
improving renal blood flow.10,38 Additionally, PTX improves inflammatory lung injury 
after chronic endotoxemia.38 Although investigators acknowledge the complexity in 
seeking treatments for endoplasmic reticulum stress,31 PTX mollifies mitochondrial 
reduction-oxidation stress in a rat model by restoring glutathione, thereby preserving 
viability of mitochondria showing inhibited respiration.7 
Pentoxifylline is a modified synthetic theobromine, which is the least toxic of the 
methylxanthines (ie, as compared to caffeine and theophylline).10 Eighty mg/kg of PTX is 
the reported toxic dose, heralded by flushing, fever, hypothermia, agitation, myoclonus, 
somnolence, loss of consciousness, seizures, hypotension, bradycardia, atrioventricular 
block, or asystole. At therapeutic doses, PTX does not have significant cardiac and 
bronchodilating effects as seen with other methylxanthines. In adults, PTX is 
contraindicated with recent cerebral hemorrhage. Importantly, significant adverse effects, 
including thrombocytopenia and bleeding, have not been reported among preterm 
neonates with sepsis or NEC after treatment with PTX.10 
A Cochrane Collaboration meta-analysis of four trials published between 1996 
through 2010 showed a beneficial association between adjunctive PTX therapy as 
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compared to placebo, both in addition to routine care, or as compared to solely routine 
care and surrogate or clinical outcomes in infants with sepsis.3 There was a statistically 
significant reduction in all-cause mortality during hospital stay among all infants as well 
as among subgroups of infants with confirmed sepsis, confirmed Gram-negative sepsis, 
and preterm infants. On the other hand, there was not a significant association 
considering the late-onset sepsis subgroup.3 The newest study included in this meta-
analysis, a quasi-randomized trial published in 2010, found a statistically significant 
reduction in duration of hospitalization among neonates with suspected sepsis treated 
adjunctively with PTX as compared to placebo, both in addition to routine care.3 
Conversely, a recent RCT among neonates with clinical and laboratory signs of infection 
did not reveal a significant association between PTX or IgM-enriched intravenous 
immunoglobulin or a combination of the two as compared to placebo, each in addition to 
routine care, and duration of hospitalization or all-cause mortality.44 
Statement of the Problem 
 Despite investigation of a plethora of adjunctive treatments for neonatal sepsis, 
some with statistical significance, none are recommended for routine use.19 With 
discordant results regarding the association between PTX as an adjunct to antimicrobial 
therapy and clinical outcomes in infants with sepsis, why are investigators encouraging 
further research?3,10,19,38 Likely, while hypotheses surmising the benefit of PTX in infants 
with sepsis are founded on basic science research, many of the studies suffer from 
selection and information bias as well as presumably being underpowered to detect a 
difference in treatment effect. 
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Most neonatal therapies, including adjunctive immunologic interventions, are 
incompletely evaluated due to issues with statistical power.38 A dual-armed trial would 
require over 800 patients to reliably detect a 10% risk difference in mortality or 
disability-free survival.38 Considering the four studies examining PTX and various 
surrogate and clinical outcomes that are included in the recent Cochrane Review, the 
primary outcomes were plasma TNF level; plasma TNF, IL-1, and IL-6 levels; all-cause 
mortality during hospital stay or development of NEC; and coagulation profile and 
disseminated intravascular coagulation incidence. The respective sample sizes were 40, 
100, 50, and 37 infants.36,42,43,45 The recent study conducted by Akdag and colleagues 
examined the association between PTX or IgM-enriched intravenous immunoglobulin or 
a combination of the two as compared to placebo and all-cause mortality with a sample 
population of 204 infants.44 
Another compelling reason for more clinical studies is the ever-changing 
characteristics of the source population, namely gestational age, birth weight, 
comorbidities, microbiological flora, and early-onset vs late-onset sepsis; an evolving 
understanding of sepsis; and novel interventions available in the NICU setting. Advances 
in technology as well as perinatal care, most notably antenatal corticosteroid and 
postnatal surfactant therapy, allow many preterm infants born in the United States to 
survive and contribute to this dynamic population.8,46 Hence, robust clinical studies 
allowing for detailed subgroup analyses will prove indispensable.31 
Hypothesis 
We hypothesize that among preterm infants with blood culture-confirmed sepsis 
who are treated with pentoxifylline plus appropriate antimicrobial therapy, as compared 
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to infants treated with placebo plus appropriate antimicrobial therapy, median duration of 
stay in the neonatal intensive care unit will be significantly reduced. 
Goals and Objectives 
The purpose of our study is to ascertain the efficacy of PTX as compared to 
placebo, both in addition to appropriate antimicrobial therapy, in reducing NICU duration 
of stay among preterm infants with blood culture-confirmed sepsis. As such, this study 
aims to clarify discordance in the existing body of literature regarding the efficacy of 
adjunctive PTX therapy among infants with sepsis. We also aim to conduct novel 
research by investigating adjunctive PTX therapy among preterm infants with blood 
culture-confirmed sepsis with unique microbiological flora and acuity of care who are 
cared for using advanced therapeutic interventions, as well as by powering our study to 
detect a difference in NICU duration of stay. By the end of our study, investigators will 
determine whether adjunctive PTX therapy as compared to placebo, both in addition to 
appropriate antimicrobial therapy, significantly reduces NICU duration of stay as well as 
determine the association between adjunctive PTX therapy and adverse events, 
morbidity, and mortality. 
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Chapter 2: Review of the Literature 
Introduction 
 We reviewed published literature from July 2014 through July 10, 2015 using 
Ovid MEDLINE and EMBASE electronic journal reference databases. We exploded and 
combined (1) “infant, newborn” and (2) “sepsis” along with (3) “phosphodiesterase 
inhibitors” or (4) “pentoxifylline” (1 and 2 and (3 or 4)) to identify articles related to 
pentoxifylline in infants with sepsis. To identify articles related to NICU length of stay, 
we exploded and combined “intensive care units, neonatal” and “length of stay.” We 
limited all searches to those conducted among humans and printed in English. To be 
comprehensive we did not specify a time limit for articles related to pentoxifylline, but 
we limited the search for NICU length of stay to articles published within the last 10 
years. Our searches returned 51 and 778 articles, respectively. We assessed titles and 
abstracts for relevance to our hypothesis while concomitantly excluding editorials, 
commentaries, conference abstracts, conference papers, and letters. We included 
systematic reviews, meta-analyses, clinical trials, expert reviews, cohort studies, cross-
sectional studies, and descriptive studies. 
Adjunctive Pentoxifylline Therapy in Infants with Sepsis 
Initial Observational Study 
 
 Prior to the 1990s, pentoxifylline was an adjunctive immunologic intervention 
untested in infants with sepsis. Synthesizing prior research showing increased TNF 
concentrations are associated with mortality rate in children with septic shock, in addition 
to research showing PTX inhibits TNF production in macrophages, Lauterbach et al 
retrospectively analyzed a cohort of infants to assess the feasibility of PTX in infants.1 
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The sample population included 30 preterm infants (defined as gestational age < 36 
weeks) with clinical signs of sepsis confirmed by positive blood culture and without 
major congenital malformation or grade III or IV IVH. Seventeen infants comprising the 
exposure group received PTX, 5 mg/kg/h for 6 hours on 3 successive days given 
concomitantly with antibiotics, in addition to supportive therapy, and were 
retrospectively compared to a group of 13 infants who had received only antibiotics and 
supportive therapy. The exposure and comparison groups were statistically similar in 
birth weight and gestational age at baseline. Mortality rate (12% vs 46%; P < 0.04), 
hypotension (18% vs 69%; P < 0.006), and metabolic acidosis (18% vs 61%; P < 0.01) 
were significantly lower in the exposure group than in the comparison group. Survival in 
the subgroup of infants with Gram-negative sepsis was significantly higher when 
comparing exposed to unexposed infants (85% vs 25%; P < 0.01). There were 
significantly more infants with neutropenia in the exposed as compared to unexposed 
group, although the trend was of moderate statistical significance (29% vs 23%; P = 
0.046). On the other hand, there were no statistically significant differences between 
exposure and comparison groups in hypoproteinemia (35% vs 38%; P = 0.057) or 
thrombocytopenia (29% vs 53%; P = 0.16). There were no reported adverse effects from 
PTX infusion, defined as hypotension, irritability, and deterioration of vital signs.1 
Since the investigators reported few baseline characteristics there could have been 
significant differences in vitality as well as other factors between groups at baseline, 
which represents selection bias and potentially introduces confounding. There may also 
have been information bias if clinicians observed the exposure group more closely than 
the comparison group for adverse effects, termed observation bias, not to mention 
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potentially deficient historical records. Additionally, both groups were given intravenous 
immunoglobulin according to identical protocols; however, intravenous immunoglobulin 
is not included in current routine care and therefore reduces external validity.2 With these 
biases and a sample population of 30 infants, the difference in mortality rate between 
exposure and comparison groups could have been distorted by confounding or resulted 
from chance alone. 
Early Experimental Studies 
 Following initial observations, Lauterbach and Zembala sought to quantify the 
association between adjunctive PTX therapy and TNF levels in infants with sepsis as well 
as further investigate the association between adjunctive PTX therapy and mortality rate 
and adverse events.3 They designed a single-center, blinded, placebo-controlled RCT and 
expanded enrollment criteria to include (1) premature infants, defined as gestational age 
< 36 weeks, (2) with suspected late-onset sepsis based on clinical signs, (3) who, if they 
exhibited abdominal distension, did not have evidence of NEC on X-ray (according to 
Bell’s criteria) while excluding infants with (1) major congenital malformation, (2) grade 
III or IV IVH, or (3) congenital infection. Forty infants who met enrollment criteria were 
assigned using a permuted block randomization scheme to either the intervention group, 
who received PTX 5 mg/kg/h for 6 hours (infusion initiated 30 minutes before antibiotic 
administration) on 3 successive days in addition to routine care, or the control group, who 
received an identical dosage and duration of saline in addition to routine care.3 
 The groups were statistically similar comparing expanded baseline characteristics, 
including birth weight, Apgar score, gestational age, symptoms of shock, hypotension, 
neutropenia, hypoproteinemia, metabolic acidosis, thrombocytopenia, abdominal 
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distension, and accompanying focal infections.3 In the PTX group, plasma TNF levels 
were significantly reduced when comparing before vs after PTX infusion on day 1 (671.5 
± 438.0 pg/mL vs 218.4 ± 195.2 pg/mL; P = 0.001) and day 3 (160.1 ± 216.2 pg/mL vs 
41.0 ± 64.7 pg/mL; P = 0.01). In the placebo group, plasma TNF levels were not 
significantly reduced after placebo infusion. The most striking comparison was between 
plasma TNF levels before the first infusion of PTX on day 1 as compared to after the last 
infusion of PTX on day 3 (671.5 pg/mL vs 41.0 pg/mL; P < 0.000004). The same 
comparison within the placebo group was not statistically significant. Therefore, PTX 
was associated with a significant reduction in plasma TNF level. Although there was a 
trend toward decreased mortality rate when comparing PTX and placebo groups (0% vs 
23%), the investigators omitted hypothesis-testing data. The mortality rate in the 
subgroup of infants with shock was significantly lower in the PTX group as compared to 
the placebo group (0% vs 75%; P < 0.04). There was a significantly higher incidence of 
clinical symptoms and radiographic signs of NEC in the placebo vs PTX group (31% vs 
6%; P < 0.004) as well as a significantly higher incidence of metabolic acidosis (P < 
0.05) and oliguria or anuria (P < 0.05) in the placebo group. The authors omitted 
treatment effect for the latter two comparisons. Pentoxifylline therapy did not elicit 
adverse effects, as defined by hypotension, irritability, and deterioration of vital signs.3 
 This pilot RCT has several limitations. Only infants with suspected late-onset 
sepsis, but not those with suspected early-onset sepsis, were enrolled in the study, which 
limits generalizability to the source population. Similarly to the prior study, all infants 
were given a single dose of intravenous immunoglobulin on the first day of therapy, 
which also limits external validity. Although the authors reported the method of random 
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sequence generation and stated that clinicians and laboratory personnel were blinded to 
treatment allocation, investigators were not explicitly blinded to treatment allocation nor 
did they describe blinding methods. This could introduce performance bias and 
overestimate treatment effect. Additionally, 11 of 40 infants enrolled in the study who did 
not have blood culture-confirmed sepsis were excluded from analysis. Not only does this 
represent attrition bias, but also per-protocol analysis as compared to intention-to-treat 
analysis decreases external validity. Last, this study was ostensibly powered to detect a 
difference in plasma TNF levels, not differences in clinically relevant secondary 
outcomes. 
 Moreover, the use of crystalloid as a placebo among preterm infants requires 
careful analysis. There is a delicate fluid balance in infants, especially those who are 
preterm and low birth weight.4 Fluid balance is even more complex in the first few days 
of life during the postnatal diuresis. Neonates are prone to disorders of sodium balance 
due to short renal tubules with limited ability to concentrate urine complicated by avid 
aldosterone secretion during a sodium load. Fluid boluses, intravenous flushes, and drugs 
suspended in isotonic fluid have the potential to cause hyperchloremic acidosis, 
hypernatremia, sodium retention, and edema.4 Most notably among extremely low-birth-
weight infants, giving excessive sodium and water expands the extracellular compartment 
and has been shown to be associated with adverse outcomes, including weight gain and 
increased risk of patent ductus arteriosus and NEC, as well as associated with a trend 
toward increased risk of BPD, intracranial hemorrhage, and death. Considering very low-
birth-weight and extremely low-birth-weight infants, daily fluid requirements during the 
first 5 days of life are approximately 80-90, 120, 150, 180, and 180 mL/kg, respectively.4 
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In the RCT by Lauterbach and Zembala, the placebo was a volume of normal saline 
comparable to PTX, so presumably 5 mL/kg/h for 6 hours.3 This equates to a daily 30 mL 
fluid load with resultant sodium load. Although this dosage and duration of normal saline 
as placebo was ethical, considering preterm infants’ delicate fluid balance a smaller fluid 
and sodium load from a placebo would be better. 
 Recognizing the association between PTX therapy and decreased levels of TNF, 
researchers next looked for additional pro-inflammatory cytokines that might be reduced 
by PTX therapy and the respective association with clinical outcomes in infants with 
sepsis.5 Lauterbach and colleagues conducted a dual-center, double-blind, placebo-
controlled RCT among preterm infants with suspected late-onset sepsis (as determined by 
clinical signs and hematologic criteria) to examine the association between adjunctive 
PTX therapy in addition to routine care, as compared to placebo and routine care, and 
plasma levels of TNF, IL-1, and IL-6; adverse effects, including metabolic acidosis, 
hypotension, disordered peripheral perfusion, oliguria or anuria, hepatic failure, 
disseminated intravascular coagulation, and NEC; and mortality rate. One hundred 
infants were randomly allocated to either the intervention group (PTX, 5 mg/kg/h for 6 
hours, on 6 successive days) or placebo group (0.9% saline at the same dosage and for the 
same duration as the PTX group). Identical bottles of PTX or placebo that were coded 
using computer-generated random numbers ensured blinding to treatment allocation and 
intervention or placebo group. Based on research that showed disturbed perfusion 
potentially diminishes penetration of antibiotics at the site of infection, along with 
research that showed PTX potentially improves tissue perfusion, in those infants with 
disordered peripheral circulation antibiotic administration was postponed by 30 minutes 
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for PTX or placebo initiation. Otherwise, medical staff administered PTX or placebo 
concomitantly with antibiotics.5 
 In the PTX group, plasma TNF levels declined steadily over 6 days of follow-up. 
There was a statistically significant reduction in plasma TNF levels when comparing 
levels before PTX infusion on the first day to levels after PTX infusion on the sixth day 
(347.2 ± 452.3 pg/mL vs 68.1 ± 127.5 pg/mL; P = 0.009).5 Tumor necrosis factor trended 
downward on day 3 and then upward on day 6 in the placebo group, but not in a 
statistically significant manner. When measured after administration of PTX or placebo 
on the sixth day, plasma IL-6 levels were significantly lower in the PTX group as 
compared to the placebo group (13.6 ± 16.6 pg/mL vs 197.5 ± 280.2 pg/mL; P = 0.04). 
Interleukin-1 trends did not differ significantly within the intervention or placebo group. 
Sepsis complicated by shock occurred in both groups, but only among the subgroup of 
infants with Gram-negative microorganisms isolated from blood culture. One of 6 infants 
in the PTX group and 4 of 8 infants in the placebo group who had symptoms of shock at 
enrollment died during follow-up; however, the difference between groups was not 
statistically significant (17% vs 50%; hypothesis-testing data omitted). Also of note, the 
mortality rate in the PTX group was significantly lower than in the placebo group, albeit 
marginally (2.5% vs 15.8%; P = 0.046). Of the other secondary outcomes, the only 
significant difference was a lower incidence of NEC in the PTX group as compared to the 
placebo group (5% vs 21%; P = 0.01).5 
 This study used similar enrollment criteria and statistical methods to the previous 
study: infants with early-onset sepsis were not included in the sample population and 10 
infants in the intervention group and 12 infants in the placebo group who did not have 
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blood culture-confirmed sepsis were excluded from analysis. One advantage of this study 
is that randomization was adequately described and investigators, medical personnel, and 
parents were blinded to treatment allocation and intervention or placebo group. Adequate 
blinding allows for a more accurate analysis of mortality differences between groups. 
Unfortunately, the investigators did not report duration of stay as an outcome. It is 
imperative to note that this study, as well as the previously discussed RCT, is ostensibly 
powered to detect a difference in the primary outcome. Therefore, differences in 
morbidity and mortality between groups must be interpreted with caution. 
 Other investigators aimed to confirm the association between adjunctive PTX 
therapy in addition to routine care and plasma TNF and IL-6 levels.6 Thirteen infants 
with suspected sepsis who were successively admitted to the study center comprised the 
exposure group while the next 7 successively admitted infants with suspected sepsis 
comprised the comparison group. Infants in the exposure group were adjunctively treated 
with PTX, 0.5 mg/kg/h for 24 hours, initiated 30 minutes prior to antibiotic therapy. The 
comparison group received solely routine care. The exposure and comparison groups 
were statistically similar comparing age at admission, gestational age, and weight at 
baseline (P > 0.05 for each comparison). Investigators report no statistically significant 
differences between exposure and comparison groups in any of the reported outcomes, 
including C-reactive protein, TNF, IL-6, leukocyte count, and mortality (0% vs 23%; P > 
0.05).6 This study potentially suffers from sampling bias, although the few reported 
baseline characteristics were similar between groups. This study is also limited by 
selection bias, performance bias, and detection bias since infants were not truly 
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randomized and the investigators were not blinded to treatment allocation or exposure or 
comparison group. As such, these results are of limited value. 
Recent Experimental Studies 
 To fill the void of studies with clinically relevant primary outcomes, Ali and 
colleagues enrolled 50 preterm infants with blood culture-confirmed sepsis but without 
IVH or congenital infection and assigned them (the authors omitted treatment allocation 
details) to either intervention (PTX, 5 mg/kg/h for 6 hours on 3 successive days given 
concomitantly with antimicrobial therapy) or control (routine care) groups.7 The 
intervention and control groups were ostensibly similar at baseline. Infants were followed 
for the duration of their hospital stay. The mortality rate in the control group was 
significantly higher as compared to the intervention group (40% vs 16%; P < 0.02). 
Similarly, the mortality rate in the subgroup of infants with Gram-negative sepsis was 
significantly higher in the control group as compared to the intervention group (53% vs 
17%; P < 0.04). There was a significantly lower incidence of NEC in the PTX group as 
compared to the control group (8% vs 28%; P < 0.01). Although there was a trend toward 
reduced duration of hospital stay (15 days vs 30 days) and reduced duration of 
mechanical ventilation (72 hours vs 120 hours) among infants treated adjunctively with 
PTX as compared to those receiving routine care, the investigators omitted hypothesis-
testing data. In agreement with all prior studies, there was no evidence of adverse effects 
from PTX, defined as hypotension, irritability, or deterioration of vital signs.7 
 While the investigators correctly identified the paucity of studies powered to 
detect a difference in mortality, their study has several limitations. First, the authors 
omitted details of randomization. Hence, there is possibly selection bias. Although 
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baseline characteristics were reportedly similar between groups, hypothesis-testing data 
were omitted so the null hypothesis cannot be reliably accepted. Timing of disease onset 
was not reported, so subgroup analysis between early-onset and late-onset sepsis could 
not be conducted. The authors also omitted whether parents, medical staff, and 
investigators were blinded to treatment allocation or outcome assessment, potentially 
introducing performance bias and detection bias as well as overestimating treatment 
effect. One advantage of this study is that all infants were included in statistical analysis, 
minimizing attrition bias and allowing for intention-to-treat analysis. Importantly, this 
study adds to the existing body of literature by reporting duration of hospital stay and 
duration of mechanical ventilation as secondary outcomes. Unfortunately, the authors did 
not include standard deviation (for parametrically distributed data), range (for 
nonparametrically distributed data), or hypothesis-testing data for either outcome. 
 Following the example set by Ali and colleagues to focus on clinically relevant 
primary and secondary outcomes, Adel et al designed a single-center, blinded, placebo-
controlled clinical trial with the goal of examining the efficacy of adjunctive PTX therapy 
as compared to placebo, both in addition to routine care, to attenuate microcirculatory 
derangement in neonates with sepsis.8 Infants were eligible for enrollment with suspected 
sepsis, but were excluded by any of the following criteria: (1) major congenital 
malformations, (2) IVH, (3) symptoms of congenital infection, or (4) treatment with 
steroids, another phosphodiesterase inhibitor, anticoagulants, or antiplatelet agents. Thirty 
seven neonates were assigned by quasi-randomization (neonates admitted to the study 
center on Tuesday or Thursday were assigned to the intervention group, while neonates 
admitted to the study center on Monday or Wednesday were assigned to the placebo 
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group) to the intervention (PTX, 5 mg/kg/h (daily required volume of PTX removed from 
ampule, diluted up to 12 mL with normal saline, and then infused at 2 mL/h) for 6 hours 
on 6 successive days given concomitantly with antimicrobials in addition to routine care) 
or placebo (normal saline, 2 mL/h for 6 hours on 6 successive days given concomitantly 
with antimicrobials in addition to routine care) group.8 The groups were ostensibly 
similar at baseline. 
Primary outcomes were coagulation parameters, as measured by prothrombin time 
(PT), activated partial thromboplastin time (aPTT), fibrinogen, and D-dimer; C-reactive 
protein (CRP); white blood cell count; and platelet count.8 The authors reported a 
moderately significant reduction in CRP between PTX and placebo groups when 
comparing levels before infusion of PTX or placebo on day 1 to after infusion on day 3 
(P = 0.045) and after infusion on day 6 (P = 0.04). Conversely, there was not a 
statistically significant difference between PTX and placebo groups considering 
fibrinogen, D-dimer, PT, aPTT, platelets, or leukocytes. Secondary outcomes were organ 
dysfunction, as measured by clinical bleeding, fresh frozen plasma requirement, 
disseminated intravascular coagulation, disordered peripheral circulation, requirement of 
inotropic agent, shock, NEC, liver failure, convulsions, or oliguria; multiple organ 
dysfunction syndrome; duration of hospitalization; and mortality. Comparing groups 
adjunctively treated with PTX vs placebo, there was a significant decrease in clinical 
bleeding, (23.5% vs 60%; P = 0.0128), fresh frozen plasma requirement (36% vs 80%; P 
= 0.003), incidence of multiple organ dysfunction syndrome (23.5% vs 55%; P = 0.037), 
and duration of hospitalization (22.6 ± 13.2 days vs 33.8 ± 16.2 days; P = 0.044).8 
Importantly, 5 infants with sepsis required adjunctive PTX therapy in order for 1 infant to 
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have a significant reduction in mean duration of hospital stay (risk difference = -0.19; 
95% CI, -0.29 to -0.08; NNT 5; 95% CI, 3-12; P = 0.04).9 There were no other 
statistically significant differences in secondary outcomes, most notably mortality, 
between intervention and placebo groups. Additionally, there were no adverse effects 
associated with PTX infusion, as measured by thrombocytopenia, cholestatic jaundice 
requiring therapy, irritability, and gastrointestinal disturbances.8  
 The first limitation of this study is that neonates were assigned to intervention or 
placebo groups by quasi-randomization as opposed to truly random treatment allocation, 
which potentially introduces selection bias. Also, while the investigators stated that 
baseline characteristics were similar between groups, hypothesis-testing data were 
omitted. Although PTX and normal saline were filled in identical syringes, performance 
bias and detection bias are concerns because the study was quasi-randomized and 
therefore blinding of medical staff and investigators cannot be reliably assessed. While 
the authors report a difference in duration of stay between PTX and placebo groups, 
application of these results is limited by the investigators’ choice to operationalize 
duration of stay as a parametric outcome measure. Operationalizing duration of stay as a 
parametric outcome measure as compared to a nonparametric outcome measure increases 
type II error and decreases explanatory power of multivariate models when raw data are 
not normally distributed, which is commonly the case in healthcare settings.10 Two 
strengths of this study are intention-to-treat analysis despite 6 of 37 infants without blood 
culture-confirmed sepsis as well as expansion of clinically relevant outcomes to include 
coagulopathy and organ dysfunction. 
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Most Current Empirical Studies 
 To inform evidence-based pharmacotherapeutic decisions for neonates with 
sepsis, the Cochrane Collaboration updated a systematic review and meta-analysis9 in 
2011 to synthesize results from selected aforementioned clinical trials. Using Mantel-
Haenszel multivariate modeling, the authors reported a statistically significant reduction 
in all-cause mortality during hospital stay among all infants with suspected or confirmed 
sepsis treated adjunctively with PTX as compared to placebo, both in addition to routine 
care, or as compared to solely routine care (pooled RR = 0.3966; 95% CI, 0.2030-0.7749; 
P = 0.007) as well as among subgroups of infants with confirmed sepsis (pooled RR = 
0.2714; 95% CI, 0.1141-0.6458; P = 0.003), confirmed Gram-negative sepsis (pooled RR 
= 0.2735; 95% CI, 0.1158-0.6462; P = 0.003), and preterm infants (pooled RR = 0.2714; 
95% CI, 0.1141-0.6458; P = 0.003).9 Conversely, there was not a significant association 
between adjunctive PTX therapy and mortality considering the late-onset sepsis subgroup 
(pooled RR = 0.1919; 95% CI, 0.0361-1.0190; P = 0.05). Duration of hospital stay was 
significantly reduced when comparing infants with suspected or confirmed sepsis treated 
adjunctively with PTX to infants given placebo, both in addition to routine care (mean 
risk difference = -11.2; 95% CI, -22.0948 to -0.3052; P = 0.04). Inspection of forest plots 
and analysis of I2 statistics did not uncover significant heterogeneity among trials for any 
comparison.9 
Despite these statistically significant associations and statistical homogeneity 
among trials, meta-analysis cannot control for source bias, previously described in detail 
for each study. Meta-analyses are also subject to publication bias. Furthermore, each of 
the trials included in this meta-analysis enrolled relatively small sample populations. 
27 
Since investigators did not justify sample sizes, statistical power to detect a difference in 
treatment effect cannot be reliably assessed. Overall, if bias, confounding, and lack of 
statistical power misconstrued results, then there may not be a beneficial association 
between adjunctive PTX therapy and clinical outcomes among infants with sepsis. 
In the conclusion of the aforesaid Cochrane Review, the authors implore future 
researchers to continue studying PTX as adjunctive therapy in neonates with sepsis, and 
perhaps to investigate it in conjunction with other promising adjunctive therapies such as 
colony stimulating factors or intravenous immunoglobulin.9 Akdag et al heeded this call 
with a single-center, blinded, placebo-controlled RCT.11 They hypothesized that among 
infants with sepsis, adjunctive therapy with PTX, immunoglobulin M (IgM)-enriched 
intravenous immunoglobulin (IVIG), or a combination of the two, as compared to 
placebo, would decrease mortality rate. To test this hypothesis, they enrolled 204 infants 
with suspected sepsis but without (1) major congenital abnormalities, (2) grade III or IV 
IVH, (3) symptoms of congenital infection, (4) inborn errors of metabolism, or (5) prior 
treatment with PTX or IgM-enriched IVIG. Enrolled infants were assigned to receive 
routine care in addition to PTX (6 mg/kg/h over 4 hours for 3 successive days), IgM-
enriched IVIG (250 mg/kg over 4 hours for 3 successive days), PTX plus IgM-enriched 
IVIG (PTX 6 mg/kg/h over 4 hours given first, followed by IgM-enriched IVIG 250 
mg/kg over 4 hours, for 3 successive days) or placebo (normal saline 5 mL/kg over 4 
hours for 3 successive days). 
While groups were statistically similar at baseline in prematurity, recurrent apnea, 
feeding intolerance, temperature instability, and glucose instability, the PTX, IVIG, and 
placebo groups were comprised of significantly more infants with lethargy than the PTX 
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plus IVIG group (P < 0.004).11 There was not a statistically significant difference in 
mortality rate between the 4 groups (PTX: 9.8% vs IVIG: 7.8% vs PTX+IVIG: 13.7% vs 
placebo: 3.9%; P > 0.05). The groups were also ostensibly similar regarding incidence of 
morbidities, including oliguria/anuria, hepatic failure, NEC, disseminated intravascular 
coagulation, and pulmonary hemorrhage, but hypothesis-testing data were omitted. 
Although there was a trend toward reduced duration of hospital stay in the PTX and 
placebo groups, the authors omitted hypothesis-testing data (PTX: median 28 days; range 
5-246 days vs IVIG: median 32 days; range 5-136 days vs PTX+IVIG: median 38 days; 
range 5-119 days vs placebo: median 27 days; range 1-168 days). Additional secondary 
outcomes included WBC count, neutrophil CD64, and plasma CRP, IL-6, and TNF levels 
measured before initiation of the study protocol on day 1 and repeated on days 2 and 4. 
There was a trend toward reduced neutrophil CD64 levels in the IVIG and PTX plus 
IVIG groups as compared to PTX and placebo groups, but the investigators did not 
clearly report treatment effect and omitted hypothesis-testing data.11 
 Although the investigators reported using cards in sealed, opaque, sequentially 
numbered envelopes to blind treatment allocation, random allocation is incompletely 
described because they did not describe the method of random sequence generation. The 
method of blinding is adequately described. Regarding sepsis diagnosis, the authors 
reported positive blood, urinary tract, cerebrospinal fluid, and catheter cultures.11 
However, sampling blood via indwelling catheters could increase false-positive cultures, 
which represent contamination, as opposed to true-positive cultures, which represent 
bloodstream infection.12 The investigators also did not specify which antimicrobials were 
administered, which limits internal and external validity.11 Three additional limitations 
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include: (1) the sample size was calculated using an estimated 50% mortality rate, based 
on 12% mortality rate from NEC, presumably to decrease sample size; (2) moderate 
statistical power (70%) to detect a difference in treatment effect; and (3) the majority of 
infants in the sample population had Gram-positive infections, while research has shown 
the most significant benefit from adjunctive IgM-enriched IVIG therapy among patients 
with Gram-negative septic shock.11 This study adds to the existing body of literature by 
investigating combined adjunctive immunologic interventions. 
Duration of Stay in Infants with Sepsis 
Economic Burden 
 
Although mortality is an irreplaceable outcome,13 with notable statistical power 
difficulty14 and mortality from newborn sepsis declining15,16 in combination with survival 
from prematurity increasing,17,18 duration of stay should be considered for primary 
outcome in clinical studies.19,20 Reducing excess duration of stay is a pragmatic goal.19-21 
Investigators explored the economic burden of bloodstream infection by retrospectively 
comparing 900 VLBW infants with or without NICU-associated late-onset bloodstream 
infection admitted to any of three NICUs in the greater Cincinnati region from 2005-
2007.21 The primary outcomes were mean, per-patient, adjusted in-hospital costs of care 
and duration of NICU stay. Among the subgroup of infants without major anomaly or 
major surgery who survived to NICU discharge, infants with NICU-associated 
bloodstream infection as compared to infants without bloodstream infection had 
significantly greater cost of care by $19 272 (mean risk-adjusted overall cost of care = 
$116 305; 95% CI, $95 336-$137 274 vs $97 033; 95% CI, $81 056-$113 010; P = 0.01) 
and significantly longer duration of NICU stay by 7 days (mean = 54 days; 95% CI, 46-
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61 days vs 46 days; 95% CI, 41-52 days; P = 0.006). Among the subgroup of infants 
without major anomaly or major surgery who died prior to NICU discharge, infants with 
NICU-associated bloodstream infection as compared to infants without bloodstream 
infection had significantly greater cost of care by $58 515 (mean risk-adjusted overall 
cost of care = $142 673; 95% CI, $102 116-$183 230 vs $84 158; 95% CI, $52 860-$115 
457; P = 0.004) and significantly longer duration of NICU stay by 28 days (mean = 53 
days; 95% CI, 35-72 days vs 25 days; 95% CI, 14-43 days; P = 0.008). The investigators 
acknowledged that NICU duration of stay is only one of many factors contributing to the 
increased costs of NICU-associated bloodstream infection.21 
Quantification in the United States 
One objective of Yale-New Haven Hospital’s single-center longitudinal database 
of neonatal bloodstream infections is to examine changes in outcomes among infants with 
sepsis.12 Infants were included in the database from 2004 through 2013 if they were (1) 
admitted to the NICU of YNHH Children’s Hospital, (2) had a traditional neonatal 
pathogen isolated from blood culture, or (3) had a commensal neonatal pathogen isolated 
from at least 1 blood culture after which appropriate antimicrobial therapy was 
administered. Infants were excluded from the database if blood cultures did not meet the 
aforementioned criteria or if isolated pathogens were believed to be contaminants (eg, 
Corynebacterium and nonspeciated Gram-positive bacilli). Additionally, infants were 
considered to have only 1 sepsis episode if multiple blood cultures drawn from the same 
infant within 7 days yielded the same species of microorganism with identical antibiotic 
susceptibility patterns. Over the 10 years spanning 2004-2013, 452 microorganisms were 
isolated during 410 sepsis episodes among 340 infants. Bizzarro and colleagues 
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interrogated the database and reported that 10% of sepsis episodes (42 of 410 sepsis 
episodes) were classified as early-onset sepsis, whereas 90% of sepsis episodes (368 of 
410 sepsis episodes) were classified as late-onset sepsis.12 Among the subgroup of infants 
with early-onset sepsis, the mean gestational age was 30 ± 6 weeks and the mean birth 
weight was 1601 ± 1108 grams, with 60% of infants (25 of 42 infants) classified as 
VLBW. Furthermore, duration of stay in the early-onset subgroup was 45.4 ± 49.9 days 
and 31% of infants (13 of 42 infants) died. Among infants with late-onset sepsis, the 
mean gestational age was 29 ± 5 weeks and the mean birth weight was 1283 ± 869 grams, 
with 72% of infants (215 of 298 infants) classified as VLBW. Duration of stay in the late-
onset subgroup was 81.8 ± 58.1 days and 21% of infants (64 of 298 infants) died.12 
This study has several limitations. First, the Centers for Disease Control and 
Prevention (CDC) updated its surveillance definition in 2008 to require 2 blood cultures 
yielding commensal pathogens, as compared to 1 blood culture after which appropriate 
antimicrobial therapy was administered, to be defined as a positive blood culture.12 
Investigators chose to use the older definition of commensal-related positive blood 
culture throughout the study period to enhance comparisons over time, but this could also 
have introduced sampling bias. Second, NICU-wide infection prevention initiatives were 
implemented in 2008 and 2009. Since these initiatives presumably contributed to a 
reduction in both true-positive and false-positive blood cultures, especially blood cultures 
isolating coagulase-negative staphylococci, there could have been a predominance of 
virulent pathogens since that time that contributed to an inflated mortality rate.12 Third, 
the database consists of information gathered from a single center as compared to 
multiple centers, which decreases external validity. 
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Other investigators conducted a retrospective analysis of VLBW infants with 
blood culture-confirmed late-onset sepsis admitted to the NICU of YNHH Children’s 
Hospital between 1989-2007 to characterize clinical and laboratory features associated 
with mortality.22 The investigators analyzed extensive demographic, antepartum, 
intrapartum, clinical, and laboratory data from 424 VLBW infants with at least 1 episode 
of monomicrobial late-onset sepsis, defined as preliminary isolation of a Gram-positive, 
Gram-negative, or fungal microorganism from blood culture. Infants with episodes of 
polymicrobial sepsis were excluded, and in infants with multiple episodes of late-onset 
sepsis during their NICU stay only the first sepsis episode was included in analysis. 
Among infants who survived sepsis, those infants with fungal sepsis had a longer 
duration of hospital stay as compared to infants with Gram-positive or Gram-negative 
sepsis (fungal: median 97 days; range 58-155 days vs Gram-positive: median 63 days; 
range 4-273 days vs Gram-negative: median 54 days; range 3-351 days; P < 0.0001).22 
The investigators also reported using logistic regression that sepsis-related mortality was 
higher among infants with Gram-negative sepsis as compared to Gram-positive or fungal 
sepsis (P < 0.0001). In total, 98 of 424 infants (23.1%) died from sepsis-related causes. 
Also of note, clinical features, laboratory features, and comorbidities associated with 
increased mortality risk included endotracheal intubation, prior antibiotic exposure, need 
for pressors, H2 blocker exposure, hypoglycemia, neutropenia, thrombocytopenia, 
leukocytosis, and concurrent NEC.22 Since this study was conducted prior to the change 
in CDC surveillance definition of commensal species-related bloodstream infection, this 
study could also have overestimated the burden of sepsis compared to the current source 
population. By applying current CDC definitions, some infants with coagulase-negative 
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staphylococci would presumably be excluded and thereby more infants with more 
virulent bloodstream infections would be included, which could prolong duration of stay 
and increase mortality rate. 
Robinson and colleagues aimed to examine the association between persistent 
candidemia as compared to non-persistent candidemia and duration of hospitalization or 
mortality.23 The investigators retrospectively examined charts from a single NICU and 
included infants with a single blood culture that yielded any Candida species; infants 
with recurrent candidemia, defined as 2 negative peripheral blood cultures between 
incidents of Candida isolated from blood culture; and infants with persistent candidemia, 
defined as a Candida-related blood culture that remained positive for > 5 days. As 
revealed by the k-sample equality of medians test, there was a trend toward prolonged 
median duration of hospitalization among infants without persistent candidemia (27 of 37 
infants) as compared to infants with persistent candidemia (9 of 37 infants), but not of 
statistical significance (median 70 days; IQR, 65-110 days vs median 90 days; IQR, 60-
90 days; P = 0.74). Five of 37 infants with candidemia (14%) died before hospital 
discharge.23 This study is limited by its retrospective design and small sample population, 
for which the authors omitted justification. On the other hand, an advantage of this study 
is that the investigators appropriately compared duration of stay between groups using 
nonparametric analysis. 
Sohn and colleagues have also reported using a point prevalence survey of 29 
NICUs within the Pediatric Prevention Network that infants in the NICU who have 
nosocomial bloodstream infections, or nosocomial infections of the ear, nose, and throat, 
lower respiratory tract, or urinary tract, have a significantly prolonged median duration of 
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stay as compared to infants without infection (median 88 days; range 8-279 days vs 
median 32 days; range 1-483 days; P < 0.001).24 There was also a trend toward increased 
mortality among infants with nosocomial infection as compared to infants without 
nosocomial infection, but not of statistical significance (treatment effect and hypothesis-
testing data omitted).24 Since a point prevalence study represents only a snapshot in time, 
these results should be interpreted with caution. 
Discharge Complexity 
Although reducing NICU duration of stay has numerous benefits, preterm infants 
of low birth weight who require NICU care as compared to healthy term infants have an 
increased risk of readmission or death after hospital discharge.25 Among extremely low-
birth-weight infants < 27 weeks gestational age, prolonged NICU duration of stay is a 
risk factor for mortality after discharge from the NICU.26 Preterm infants are 1 of 4 high-
risk categories of infants who have complex needs regarding NICU discharge.25 This 
requires individualized planning and the attending neonatologist’s expertise to weigh the 
risks, benefits, and alternatives of expedited discharge from the NICU to ensure the 
infant’s best medical interests and the family’s preparedness to care for their infant at 
home.25  
Additional Potential Confounding Variables 
 Many studies explore myriad variables associated with duration of stay, 
morbidity, or mortality among premature and low-birth-weight infants. Lee et al 
interrogated data from the California Perinatal Quality Care Collaborative, comprising 
129 NICUs, to model NICU duration of stay among extremely low-birth-weight infants 
weighing 401-1000 grams.27 The investigators examined diverse variables, including 
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maternal characteristics and intrapartum variables (maternal age, race/ethnicity, prenatal 
care, location of birth, antenatal steroid use, multiple gestation, delivery mode, antenatal 
conditions), delivery room variables (Apgar score), and infant characteristics (gender, 
birth weight, gestational age, and small for gestational age). Of many significant 
associations, birth weight (P < 0.0001), gender (P < 0.0001), small for gestational age (P 
< 0.0001), black race/ethnicity (P = 0.0007), antenatal steroid use (P = 0.0098), fetal 
distress (P < 0.0001), maternal hypertension (P < 0.0001), 5-minute Apgar score ≤ 3 (P = 
0.0003), and 5-minute Apgar score 4-7 (P < 0.0001) most closely predicted length of stay 
in the final risk-adjusted model. There was also significant variation in length of stay 
between hospitals.27 Another study among VLBW infants (defined as 501-1500 grams) 
compared data gathered from 1995-1996 to that of 1997-2002 with the aim of 
investigating trends in morbidity and mortality.17 Comparing the later to the earlier 
period, survival increased for multiple births (26% vs 22%; P < 0.05), antenatal 
corticosteroid use (79% vs 71%; P < 0.05), and maternal antibiotics (70% vs 62%; P < 
0.05).17 Inguinal hernia and patent ductus arteriosus are also associated with longer 
duration of stay among VLBW infants.28 
Multiple studies designed to investigate duration of hospital stay or mortality 
among premature infants 23-36 weeks gestational age confirm the importance of 
variables reported in studies among low-birth-weight infants, including maternal age, 
race/ethnicity, prenatal care, location of birth (inborn/outborn), antenatal steroid use, 
multiple gestation, delivery mode (vaginal vertex/vaginal breech/cesarean section), Apgar 
score, gender, birth weight, gestational age, small for gestational age, BPD, IVH, NEC, 
and specific hospital.20,29-32 These studies also uncover novel variables related to duration 
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of stay. Hintz and colleagues reported using a generalized linear model for predicting 
time to hospital discharge that among infants 25-26 weeks gestational age the odds of 
early hospital discharge were significantly lower without maternal insurance coverage 
(OR = 0.40; 95% CI, 0.29-0.54; P < 0.012), with chest compression and/or drugs for 
resuscitation (OR = 0.47; 95% CI, 0.25-0.86; P < 0.014), and with diagnosis of patent 
ductus arteriosus (OR = 0.65; 95% CI, 0.46-0.93; P < 0.018).20 Additionally, late-onset 
sepsis (OR = 1.45; 95% CI, 1.04-2.01; P = 0.028), BPD (OR = 4.17; 95% CI, 2.84-6.13; 
P < 0.001), postnatal steroids (OR = 1.67; 95% CI, 1.06-2.62; P = 0.026), stage III 
retinopathy of prematurity (OR = 1.69; 95% CI, 1.10-2.56; P = 0.014), and surgery for 
retinopathy of prematurity, NEC, or patent ductus arteriosus (OR = 2.73; 95% CI, 1.85-
4.03; P < 0.001) were positively associated with late discharge.20 Among neonates ≤ 28 
weeks gestational age, the odds of prolonged hospital stay were significantly higher with 
2 or more doses of surfactant (OR = 1.50; 95% CI, 1.17-1.93) and significantly lower 
with birth in 1999 vs 1998 (OR = 0.63; 95% CI, 0.46-0.87).31 
Altman and colleagues focused their investigation on moderately preterm infants 
30-34 weeks gestational age and found that infants with hyperbilirubinemia (P < 0.01) or 
respiratory distress syndrome (P < 0.001) had a significantly higher postmenstrual age 
(gestational age plus postnatal age)33 when discharged from the hospital.29 Conversely, 
infants who received breast milk exclusively or in part as compared to those who did not 
receive breast milk were discharged from the hospital with a postmenstrual age 2.7 days 
lower (P < 0.001). However, the difference between postmenstrual age at discharge 
between infants who received breast milk as compared to infants who did not receive 
breast milk decreased to 1.9 days when controlling for maternal risk factors and neonatal 
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morbidity in multivariate analysis.29 Other variables among infants 32-36 weeks 
gestational age reported to influence duration of stay or morbidity include antepartum 
hemorrhage, including placenta previa and placental abruption,34,35 oligohydramnios, 
intrauterine growth restriction, and maternal hypertension, including chronic 
hypertension and hypertensive disease of pregnancy.35 Considering both preterm and 
term infants, hospital discharge rates were significantly lower on the weekends as 
compared to the weekdays, which also influences duration of stay.36 
Transfer from an outside facility,37,38 variations in neonatal medical practice,39 
even as simple as varying definitions for apnea,40 or uncharacterized differences between 
NICUs20,27,32 confound duration of stay20,27,32,37,38,40 and mortality.37 Lead-time bias, in 
which appropriate interventions are initiated earlier in a patient transferred from an 
outside medical facility, as compared to infants admitted directly or from the emergency 
department, could explain differences in outcomes.37 Moreover, some centers refer only 
the sickest infants to tertiary care centers while others refer only vigorous infants.31 
Conclusion 
 Three studies investigating the efficacy of adjunctive PTX therapy as compared to 
placebo, both in addition to routine care, or as compared to solely routine care in infants 
with sepsis have revealed varying differences in duration of hospital stay between groups. 
Some investigators have reported a significant reduction in duration of hospital stay when 
comparing adjunctive PTX and placebo groups8 (mean 22.6 days ± 13.2 days vs mean 
33.8 days ± 16.2 days; mean difference = -11.2; 95% CI, -22.0948 to -0.3052; P = 0.04),9 
while other investigators have reported a trend toward reduced duration of hospital stay 
in the adjunctive PTX group as compared to the routine care group (15 days vs 30 days)7 
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or a similar duration of hospital stay between groups (PTX: median 28 days; range 5-246 
days vs placebo: median 27 days; range 1-168 days; P > 0.05).11 Considering the former 
two studies, when comparing PTX and control groups duration of hospital stay was 
reduced by 33% and 50%, respectively. Unfortunately, these studies bear substantial 
sampling, selection, and information bias from nonrandom sampling of participants, 
improper randomization techniques, inadequate blinding to intervention and control 
groups, improper statistical operationalization of duration of stay, and incompletely 
reported hypothesis-testing data. There was also presumably limited ability to detect a 
difference in treatment effect since duration of stay was a secondary outcome, not to 
mention sample sizes were rarely justified. Without appropriate sampling, true 
randomization, adequate blinding, assessment of many confounding variables, and 
justified, appropriate sample sizes these clinical trials had limited internal and external 
validity and overestimated differences in duration of stay, morbidity, and mortality 
between intervention and control groups. Inferences about the efficacy of adjunctive PTX 
therapy to the source population are tenuous. The question remains unanswered as to 
whether a clinical trial with improved internal and external validity and sufficient power 
to detect a difference in treatment effect will confirm or refute the reduction in duration 
of stay associated with adjunctive PTX therapy among infants with sepsis. 
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Chapter 3: Study Methods 
Study Design  
We propose a multicenter, double-blind, placebo-controlled, parallel-group 
randomized controlled trial among preterm infants with blood culture-confirmed sepsis to 
investigate the efficacy of PTX plus appropriate antimicrobial therapy, as compared to 
placebo plus appropriate antimicrobial therapy, to reduce median duration of stay in the 
neonatal intensive care unit (see Appendix B). 
Study Population and Sampling 
The source population will consist of preterm infants with blood culture-
confirmed sepsis. The study population will consist of preterm infants with blood culture-
confirmed sepsis being cared for in the NICU of Yale-New Haven Hospital Children’s 
Hospital, Bridgeport Hospital, Lawrence and Memorial Hospital, or one of two campuses 
of Connecticut Children’s Medical Center, including Hartford Hospital and University of 
Connecticut Health Center. We will consecutively sample infants from this study 
population who fulfill eligibility criteria. 
Infants will be empirically evaluated for sepsis when born preterm, if born to a 
mother with chorioamnionitis, or with clinical and hematologic criteria indicating 
neonatal sepsis (see Appendix A), each at the discretion of the attending neonatologist. A 
sepsis evaluation will consist of (1) a complete blood count, (2) two peripheral blood 
cultures (each with a minimum of 0.5 mL) collected using sterile technique, and (3) urine 
and cerebrospinal fluid cultures and an abdominal X-ray to investigate urinary tract 
infection, meningitis, and NEC (defined as pneumatosis intestinalis on X-ray), 
respectively, as determined by the attending neonatologist. Each sepsis evaluation will be 
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considered a separate event, so that an individual infant will be eligible for enrollment at 
each sepsis evaluation during his or her NICU stay. 
Inclusion criteria will be: (1) viable infant, defined as the ability, after delivery, to 
survive (given the benefit of available medical therapy) to the point of independently 
maintaining heartbeat and respiration; (2) who is preterm (< 37 weeks gestational age); 
(3) with blood culture-confirmed sepsis (see below); and (4) with legally effective 
parental informed consent (see Appendix C). Blood cultures will be assessed for carbon 
dioxide with a fluorescent-detection system. Blood culture-confirmed sepsis will be 
defined as at least 1 positive preliminary blood culture, defined as isolation of a 
traditional Gram-positive, Gram-negative, or fungal microorganism. Diagnosis of 
bloodstream infection with commensal species (eg, coagulase-negative staphylococci) 
will comply with the updated CDC surveillance definition, which requires commensal 
species to be isolated from at minimum 2 blood cultures to qualify as a positive blood 
culture. 
Infants will be excluded from enrollment by any of the following: (1) admitted to 
the NICU for preterminal comfort care (defined as neither intubation nor cardio-
respiratory resuscitation); (2) suspected or proven congenital or chromosomal anomalies 
(defined as anomalies detected at birth involving at least a single organ or organ system); 
functional states, such as patent ductus arteriosus, will not be defined as anomalies; (3) 
prior surgery, defined as procedures performed in an operating room, not to include 
bedside procedures or circumcision; (4) transferred from an outside medical facility; (5) 
grade III (defined as blood in the ventricles with ventriculomegaly) or grade IV (defined 
as blood/echodensity in the parenchyma) IVH; (6) prior treatment with PTX; (7) enrolled 
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in a competing study; or (8) parental refusal. Infants who fulfill all inclusion criteria and 
no additional exclusion criteria will be enrolled in the proposed study. 
Subject Protection and Confidentiality 
 The proposed study protocol will first be reviewed and approved by the Pediatric 
Protocol Review Committee and then by the Institutional Review Board (IRB) at each of 
the 5 study centers prior to initiating the study. Legally effective informed consent (see 
Appendix C) will be obtained from the newborn’s parent(s), or if neither parent is able to 
consent because of unavailability, incompetence, or temporary incapacity, then from her 
or his legally authorized representative. If the pregnancy resulted from rape or incest then 
legally effective informed consent from the father or his legally authorized representative 
is unnecessary. The informed consent document will be signed and dated by one of the 
aforementioned individuals as well as by the individual obtaining informed consent. 
Informed consent documentation will be written in a language that is understandable to 
the parent or her or his legally authorized representative and will not contain exculpatory 
language. If the parent or legally authorized representative does not speak English, a 
certified bilingual translator will be present to facilitate the informed consent process. 
Furthermore, if the participant is of limited reading ability then an impartial witness will 
be present during the informed consent process and will also sign and date the informed 
consent document. Participants will be given a copy of the signed and dated consent 
document. 
An independent data and safety monitoring board (DSMB), consisting of at 
minimum a neonatologist, pediatric infectious disease specialist, and statistician, will 
analyze unblinded data as it accrues once 58 infants (one-third of the predetermined 
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sample population) and again when 116 infants (two-thirds of the predetermined sample 
population) are recruited for the study to assess benefit or harm to participants. If the 
DSMB uncovers new information that may impact parents’ willingness to allow their 
infants to continue involvement in the proposed study, then revised consent will be 
reviewed and approved by the IRB at each study center and signed by participants’ 
parent(s). Consent documentation will also be modified for future participants. The study 
will be discontinued if the DSMB determines that significant benefit or harm exists in 
either the intervention or control group such that participants’ parent(s) can no longer be 
reasonably assured equipoise and safety. 
A unique study identification number, as opposed to personally identifiable 
information, will identify study participants. In accordance with Health Insurance 
Portability and Accountability Act regulations, personally identifiable information and 
protected health information will be securely stored in a locked file cabinet or in a 
password-protected file on a password-protected computer and will only be accessible by 
the principal investigator, predetermined research staff, and the DSMB. 
Recruitment 
Recruiters will screen all infants admitted for any reason to the NICU of each 
study center. Recruiters will approach the mothers (or fathers, as previously described) of 
infants who are viable, preterm, and who do not fulfill any additional exclusion criteria. 
After legally effective informed consent is obtained, when the infant is confirmed to have 
sepsis by positive blood culture then the infant will be enrolled in the study. 
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Methodology Considerations 
Allocation and Blinding 
 
After enrollment each participant will be assigned a unique study identification 
number through a random number generator. Next, a computer program will be used to 
randomly select identifiers for the PTX and placebo groups. The principal investigator 
will hold the key linking study participants to their study identification number. 
Investigators will be blind to treatment allocation. An independent pharmacist who is 
neither part of the investigation team nor part of participants’ treatment teams will apply 
an adhesive label bearing the participant’s name and medical record number to an 
identical, opaque, unmarked infusion of PTX or placebo, as selected by the computer 
program. A research assistant will then hand deliver the infusion to the participant’s 
assigned nurse and remain in the NICU until the nurse confirms that the infusion was 
initiated. As such, all parties involved in the proposed RCT, including investigators, 
parents, and medical personnel (such as phlebotomists, nurses, and clinicians) will be 
blind to group assignment. Investigators, parents, and medical personnel cannot be blind 
to primary or secondary outcome assessment. 
Adherence 
 If at any time during the study the attending neonatologist in charge of the 
participant’s care decides that it is in a participant’s best interests to be removed from the 
study, then the infant will be removed. Attending neonatologists will make this decision 
based on adverse events and morbidity (see Secondary Outcomes) as well as overall 
clinical judgment. Since the intervention and placebo will confer a daily 12 mL fluid load 
and resultant sodium load for 6 successive days, the attending neonatologist might need 
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to remove participants, especially those who are extremely low birth weight, from the 
study based on electrolyte imbalance (eg, hypernatremia, hyperchloremia, etc). Dedicated 
research assistants will monitor adherence by recording the administration site, dosage, 
and duration by which study participants receive either PTX or placebo. 
Routine Care 
Goals of routine care will be to maintain adequate systematic oxygenation and 
peripheral perfusion and eradicate the bloodstream infection. As with any neonatal 
emergency, the first step will be to secure the airway, ensure breathing, and facilitate 
circulation. Supplemental oxygen or noninvasive or invasive mechanical ventilation will 
be used to maintain systemic oxygenation. Extracorporeal membrane oxygenation is an 
alternative therapeutic intervention that may be considered in some patients to maintain 
systematic oxygenation after maximal medical therapy fails. Intravenous fluid 
resuscitation with isotonic saline or other crystalloids in 10-mL/kg bolus(es) in 
conjunction with inotropes and steroids, as needed, will be used to maintain peripheral 
perfusion. Inotropes (with dopamine as a typical first-line agent and dobutamine, 
epinephrine, or vasopressin as second-line agents) will be given preferentially by central 
venous access as opposed to peripheral intravenous or, much less commonly, via 
intraosseous access. 
Empirical treatment with parenteral broad-spectrum antimicrobials will be 
initiated when an infant is suspected of having sepsis. Antimicrobial choice will be 
guided by the anticipated pathogen, local susceptibility data, and presumed nidus of 
infection. Antimicrobial dosing is dependent upon an infant’s postmenstrual age. 
References will be available to aid clinicians with dosing. Once preliminary blood 
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cultures are positive, parenteral antimicrobial therapy will be adjusted according to the 
sensitivity pattern of the isolated microorganism. Antimicrobial therapy is typically given 
for a minimum of 10 to 14 days after blood cultures become negative, but complications 
such as meningitis may require a longer course. 
Study Variables and Measures 
Intervention 
 
 The intervention will be an intravenous infusion of pentoxifylline, 5 mg/kg/h 
(daily required volume of PTX will be diluted up to 12 mL using 0.9% sodium chloride 
and infused at a rate of 2 mL/h), initiated when sepsis is confirmed by positive blood 
culture and continued for 6 hours on 6 successive days, given concomitantly with 
appropriate antimicrobial therapy. 
Placebo 
The placebo will be an intravenous infusion of 0.9% sodium chloride, infused at a 
rate of 2 mL/h, initiated when sepsis is confirmed by positive blood culture and continued 
for 6 hours on 6 successive days, given concomitantly with appropriate antimicrobial 
therapy. 
Primary Outcome 
The primary outcome will be NICU duration of stay, defined as the number of 
days of NICU care with day 1 beginning the day of admission to the NICU, incrementing 
at midnight, and ending with discharge from the NICU or death. Neonatal intensive care 
unit duration of stay will be the sum of days of care within the study center NICU plus 
days of convalescent care in a community NICU, if applicable. The attending physician 
in charge of the participant’s care will determine the participant’s suitability for discharge 
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from the NICU. Death will be defined as in-hospital mortality from any cause before 
discharge from the NICU.  
Secondary Outcomes 
Adverse events, morbidity, and mortality will be secondary outcomes used to 
quantify the safety and efficacy of the intervention. Adverse events will include allergic 
reaction (defined as urticarial or morbilliform rash, toxic epidermal necrolysis, or 
anaphylaxis), feeding intolerance (defined as tenderness, distension, or increased or 
absent bowel sounds on abdominal examination; emesis; any change in frequency of 
stools, frank blood in stools, or guaiac positive stools), hypotension (defined as decrease 
in blood pressure < fifth percentile for age, or systolic blood pressure > 2 standard 
deviations less than normal for age, or mean arterial pressure < 30 mm Hg with capillary 
refill time > 4 seconds), neutropenia (defined as absolute neutrophil count < 2000/mm3), 
thrombocytopenia (defined as platelet count < 80 000/mm3), hypoproteinemia (defined as 
total plasma protein level < 5 g/l), metabolic acidosis (defined as pH < 7.25), renal 
insufficiency (defined as serum creatinine > 2 times upper limit of normal for age, 2-fold 
increase in baseline creatinine, or urine output < 1 mL/kg/h), disordered peripheral 
circulation (defined as mottled skin with capillary refill > 4 seconds), hepatic failure 
(defined as 50% increase in alanine aminotransferase over baseline value or international 
normalized ratio > 2), cholestatic jaundice requiring phototherapy, duration of 
supplemental oxygen (days), and duration of assisted ventilation (days). 
Morbidity will include disseminated intravascular coagulation (defined as 
generalized hemorrhagic diathesis with bleeding from venipuncture sites, 
hypofibrinogenemia < 150 mg/dl, elevated fibrin split products > 10 μg/mL, platelets < 
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100 x 103/mm3, and prolonged aPTT or PT for age), multiple organ dysfunction 
syndrome (defined as organ dysfunction in ≥ 2 organ systems), any grade (I-IV) IVH, 
periventricular leukomalacia (defined as characteristic cranial ultrasound, CT, or MRI), 
Bell’s stage II or greater NEC, respiratory distress syndrome (defined as respiratory 
distress and characteristic chest radiograph), BPD (defined as oxygen requirement at 36 
weeks postmenstrual age), any stage (I-V) retinopathy of prematurity, patent ductus 
arteriosus (defined as required treatment for patent ductus arteriosus), and mortality 
(defined as in-hospital mortality from any cause). 
Data Collection 
 First, dedicated research assistants will be trained in clinical definitions for all 
data to be collected. These trained research assistants will then abstract and de-identify 
data concerning baseline variables (see Appendix D) and primary and secondary 
outcomes by retrospectively reviewing the mothers’ medical records and prospectively 
reviewing the participants’ medical records. Research assistants will gather data from 
participants’ entire hospital course. If an infant is transferred to a community NICU for 
convalescent care then research assistants will record both the transfer date from the 
study center NICU and the admission and discharge date from the community NICU. For 
those infants who die during follow-up, research assistants will record the presumed 
cause of death or the cause of death as noted on autopsy, if available. To improve validity 
of outcome assessment, an independent committee that is blind to group assignment will 
adjudicate the primary and secondary outcomes. 
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Sample Size Calculation 
 The proposed study will be powered to detect a difference in median NICU 
duration of stay between PTX and placebo groups. Based on the most recently published 
study conducted in the NICU at YNHH, infants with a mean gestational age of 29.1 
weeks and a mean birth weight of 1314.8 grams who have blood culture-confirmed early-
onset or late-onset sepsis are treated with routine care in the NICU for an average of 78 
days. The intervention is estimated to reduce NICU duration of stay by 10%. Assuming a 
2-tailed α error of 5%, the proposed study will have 80% power to detect an 8 ± 14-day 
reduction in NICU duration of stay with a crude sample population of 100 infants, 50 in 
each group. Power and Precision statistical software was used to calculate this sample 
size (see Appendix E). The final sample size will be 15% greater than the crude sample 
size to detect a difference in median, as compared to mean, NICU duration of stay. We 
are planning for a priori 5% drop out. In addition, we plan to have 80% power for 
secondary analysis of surviving infants while excluding an estimated 22% of the sample 
population who may die during follow-up, which is a liberal estimate of mortality rate 
based on recent data. Multiplying the crude sample size of 100 infants by the inverse of 
one minus 0.42 yields the final sample size of 174 infants, 87 in each group. 
Analysis 
 Primary analysis will be performed according to the intention-to-treat principle 
using the most current version of Statistical Analysis System. For univariate analysis of 
baseline characteristics, we will test for differences between groups in categorical 
variables using the χ2 test or Fisher Exact test, as appropriate, differences in continuous 
variables using the unpaired t test, and differences in ordinal variables using the 
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Wilcoxon rank sum test. Central tendency of NICU duration of stay will be reported as a 
median and interquartile range. We will perform a test of normality on raw NICU 
duration of stay data before performing bivariate analysis. Next, we will use the 
Wilcoxon rank sum test for unadjusted analysis of median NICU duration of stay 
between intervention and placebo groups. We will log transform raw NICU duration of 
stay data prior to multivariate analysis. We plan to use multiple linear regression to 
control for potential confounding variables (as determined by univariate comparisons 
with P ≥ 0.05) when comparing NICU duration of stay between groups. If data is highly 
skewed and linear regression cannot accurately model NICU duration of stay, we will 
improve goodness-of-fit using negative binomial regression or Poisson regression. Since 
it is difficult to quantify differences in care between centers, we predetermine to stratify 
multivariate analysis by study center. We will perform subgroup analysis of NICU 
duration of stay between infants with early-onset vs late-onset sepsis; between infants 
with Gram-positive vs Gram-negative vs fungal sepsis; between cohorts of birth weight; 
between cohorts of prematurity; as well as analysis of only those infants who remain in 
the NICU for their entire duration of stay while excluding infants who die during follow-
up. Since adverse events, morbidity, and mortality are dichotomous outcome measures, 
we will test for unadjusted differences between intervention and placebo groups using the 
χ2 test and use multiple logistic regression for multivariate models that control for 
potential confounding variables (as determined by univariate comparisons with P ≥ 0.05). 
Timeline and Resources 
To adhere to the allocated 2-year timeframe for recruitment through follow-up, 
we will utilize NICUs housed within 5 local study centers. There were 410 episodes of 
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blood culture-confirmed sepsis at YNHH Children’s Hospital 54-bed NICU between 
2004-2013, which equates to 68 opportunities for recruitment over 20 months if sepsis 
episodes are evenly distributed. Each of the other 4 study centers has approximately half 
as many NICU beds as YNHH. We will assume an equivalent incidence of blood culture-
confirmed sepsis at each center, providing a pool of 204 infants for recruitment over 20 
months. Based on recent trials of therapeutic interventions in term and preterm infants in 
the NICU, we estimate 10% parental refusal rate. As such, we can feasibly complete 
rolling recruitment of 174 participants over the course of 20 months, with the last 
enrolled participants completing their NICU stay within the allocated timeframe. 
To complete our study, we will require dedicated research assistants, certified 
bilingual translators to assist with the informed consent process, an independent DSMB, 
an independent pharmacist who is neither part of the investigation team nor part of 





Chapter 4: Conclusion 
Advantages 
 The first advantage of the proposed study is its novelty in being powered to detect 
a difference in NICU duration of stay among preterm infants with blood culture-
confirmed sepsis who are unique in their microbiological flora and acuity of care and 
who are cared for using advanced therapeutic interventions. Unlike prior studies, 
enrollment criteria will not be restricted by timing of disease onset, which helps control 
for inclusion bias,1 allows for more detailed subgroup analysis, and improves external 
validity. The proposed study further improves upon similar studies by ensuring true 
randomization and successful blinding to intervention and placebo groups, log 
transforming raw NICU duration of stay data for statistical analysis, and justifying an 
appropriate sample size based on available evidence. The proposed study thereby 
improves internal validity and augments generalizability to the source population. We 
also systematically assessed potential confounding variables to improve the validity of 
multivariate comparisons of NICU duration of stay, adverse events, morbidity, and 
mortality between PTX and placebo groups. Another advantage of the proposed study is 
that infants will be followed for the duration of their hospital course until discharge from 
either the study center NICU or a community NICU. This helps to prevent potential bias 
toward an underestimation of treatment effect. If infants who are transferred to 
community NICUs were not included in follow-up, this would potentially increase the 




 The proposed study is subject to sampling bias because attending neonatologists, 
despite having validated clinical signs and hematologic criteria to guide decisions about 
which infants to evaluate for sepsis, must often rely on their clinical discretion to guide 
these decisions. The known high false-negative rate of blood cultures is another source of 
sampling bias.3,4 Both sources of sampling bias could exclude infants who have a 
bloodstream infection from enrollment, thereby decreasing external validity. There is 
potential bias toward an overestimation of treatment effect when infants die during 
follow-up. This could decrease the number of acutely ill infants who require longer NICU 
duration of stay.2 Moreover, including only infants with blood culture-confirmed sepsis, 
as compared to also including infants with suspected sepsis, underestimates the true 
burden of neonatal sepsis within the NICU and could potentially overestimate treatment 
effect.5 To investigate potential overestimation of treatment effect resulting from in-
hospital mortality, we predetermine to increase the sample size by 22% for subgroup 
analysis with 80% power to detect a difference in treatment effect while excluding infants 
who die during follow-up. Even within 1 study center, let alone between multiple study 
centers, duration of stay is potentially confounded by heterogeneous medical care, 
prognosis, resource allocation, ethical approaches, and clinicians’ and parents’ attitudes 
about intensive care among premature and VLBW infants born at the threshold of 
viability.1,2,6-9 Heterogeneity between centers limits generalizability to the source 
population.10 Nurse staffing levels1,11 and unit census11 also influence patient outcomes 
but will not be measured in the proposed study. Despite our best effort to recognize 
potential confounding variables and sources of bias, duration of stay is a composite 
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outcome influenced by many variables, even those unforeseen. Additionally, this study 
will not be powered to detect a difference between groups in important secondary 
outcomes, including adverse events, morbidity, and mortality. As a result of the 2-year 
timeframe for recruitment through follow-up, we cannot gather data on long-term 
neurological outcomes.12 
Clinical and Public Health Significance 
Assuming a conservative estimate of daily NICU costs of care ($1250 per day)10 
and a potentially 8-day shorter NICU duration of stay among infants adjunctively treated 
with PTX yields a cost savings of $10 000 per infant. With the most conservative 
estimate of neonatal sepsis incidence in developed counties (1 in 1000 live births)12 and 3 
953 593 annual live births in the United States in 2011,13 approximately 3954 infants 
suffer from sepsis each year. If each of these infants required prolonged NICU care, the 
proposed intervention could attenuate socioeconomic burden by approximately $40 
million annually. With more liberal estimates of 0.004% neonatal sepsis incidence12 and 
$2000 daily NICU costs of care,10 8 fewer days of care in the NICU among infants 
adjunctively treated with PTX could reduce healthcare system costs by approximately 
$253 million each year. In addition to socioeconomic impact, reducing duration of stay 
could also ease parental anxiety and promote bonding between infants and their 
parents,10,14 potentially enhancing critical parenting skills.10 Finally, clinicians may be 
able to answer more confidently and hopefully when parents frequently ask, “When will 
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Appendices 
Appendix A: Clinical Signs and Hematologic Criteria of Neonatal Sepsis 
 
Clinical Signs Hematologic Criteria 
Respiratory compromise 
• Tachypnea (respiratory rate of > 
60/min) 
• Increased apneas (cessation of 
respiration ≥ 20 seconds occurring 
at a rate of ≥ 2/h) 
• Severe apneas (any single episode 
requiring positive pressure 
ventilation) 
• Increased ventilatory support (with 
no other obvious cause, eg, 
pneumothorax) 
• Increased desaturations (pulse 
oximetry readings ≤ 85%) 
Cardiovascular compromise 
• Bradycardia (heart rate < 100 
beats/min) 
• Pallor 
• Decreased perfusion (capillary 
refill ≥ 3 seconds or cold 
extremities) 
• Hypotension (defined by age-
specific percentiles for neonates) 
Metabolic changes 
• Hypothermia  
(rectal temperature < 36°C) 
• Hyperthermia  
(rectal temperature > 38°C) 
• Feeding intolerance (increased 
gastric residuals of > 30% of the 
volume of food in at least 2 
feedings in 24 hours) 
• Glucose instability (blood sugar < 
45 mg/dL or > 125 mg/dL) 




• Decreased activity 
 
• Absolute neutrophil count  
(ANC) < 7500/mm3 OR > 14 500/mm3 
• Absolute band count  
(ABC) > 1500/mm3 
• Immature to total neutrophil ratio  
(I/T ratio) > 0.16 





























































1-Preterminal comfort care 
2-Suspected or proven congenital or 
chromosomal anomaly 
3-Prior surgery, excluding bedside 
procedures or circumcision 
4-Transferred from an outside medical 
facility 
5-Grade III/IV IVH 
6-Prior treatment with pentoxifylline 
7-Enrolled in a competing study 
8-Refused to participate 
9-Other reasons 
Assessed for eligibility of NICU patients cared for at: 
1-Yale-New Haven Hospital Children’s Hospital 
2-Bridgeport Hospital 
3-Lawrence and Memorial Hospital 
4-Hartford Hospital 
5-University of Connecticut Health Center 
 
174 Randomized 
87 Randomly allocated to 
receive placebo plus  
routine care 
 
     Received placebo 
 

























87 Randomly allocated to 
receive pentoxifylline plus 
routine care 
 
     Received pentoxifylline 
 
Did not receive 
pentoxifylline 
Analyzed 
     Discharged from NICU 
     In-hospital mortality 
 
Excluded from analysis 









     Discharged from NICU 
     In-hospital mortality 
 
Excluded from analysis 
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Appendix C: Informed Consent 
COMPOUND AUTHORIZATION AND PARENTAL PERMISSION 
FOR PARTICIPATION IN A RESEARCH PROJECT 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
YALE-NEW HAVEN HOSPITAL 
BRIDGEPORT HOSPITAL 
LAWRENCE AND MEMORIAL HOSPITAL 
HARTFORD HOSPITAL 
UNIVERSITY OF CONNECTICUT HEALTH CENTER 
 
Study Title: Pentoxifylline as an Adjunct to Antimicrobial Therapy to Reduce Length of 
Stay in Infants with Sepsis 
Principal Investigators: Philip J. Yinger, PA-SII; Lindsay C. Johnston, MD 
Funding Source: Yale University School of Medicine Physician Associate Program 
 
Parental Permission - Invitation to Have Your Child Participate in a Research 
Project and a Description of the Project 
 
The purpose of this consent form is to provide you with the information you need to 
consider in deciding whether to allow your child to participate in this research study. 
 
We are inviting your child to participate in a research study designed to reduce the number 
of days your child needs to be cared for in the neonatal intensive care unit should your 
child develop an infection called sepsis, which can occur when there are harmful 
substances (bacteria or fungi) in the blood. You have been asked to participate because 
your child is being cared for in the neonatal intensive care unit (NICU) and might develop 
sepsis. You are under no obligation to participate and, if you decide not to participate, it 
will not affect your child’s care in any way. 
 
In order to decide whether you wish for your child to be a part of this research study you 
should know enough about its risks and benefits to make an informed decision. This 
permission form gives you detailed information about the research study, which a member 
of the research team will discuss with you. This discussion should go over all aspects of 
this research: its purpose, the procedures that will be performed, any risks of the 
procedures, possible benefits, and possible alternative treatments. Once you understand the 
study, you will be asked if you wish for your child to participate. If so, you will be asked 
to sign this form and will be given a copy to keep as a record. 
 
Description of Procedures 
Your child’s participation in this study involves obtaining a complete medical history, 
including maternal health records such as demographic and pregnancy/delivery details. 
We will review your child’s and the mother’s medical records to look for factors other 
than the medicine we are studying that could influence the number of days your child is 
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cared for in the NICU. The study will include a total of 174 patients admitted to the 
NICU at Yale-New Haven Hospital Children’s Hospital, Bridgeport Hospital, Lawrence 
and Memorial Hospital, Hartford Hospital, or University of Connecticut Health Center. If 
your child’s medical team is concerned that your child could have an infection in his/her 
blood, they will draw blood to test for the presence of an infection. Your child’s medical 
team will also give your child antibiotics as per routine care. If the clinical laboratory 
finds harmful substances (bacteria or fungi) in your child’s blood, then your child will 
continue to be given antibiotics for approximately 10 to 14 days. 
 
If you decide to have your child participate in this study, when the clinical laboratory 
confirms that your child has an infection in his/her blood then your child will continue to 
receive antibiotics as per routine care. At the same time, we will use a computer to 
randomize (like flipping a coin) your child to be given either pentoxifylline (PTX) or 
placebo, both for 6 days, through an intravenous (inside the vein) site. The research staff 
and medical team will be blind to which substance your child is given, meaning they will 
not know whether your child receives PTX or placebo. The entire time your child is being 
cared for in the NICU neither the research staff nor the medical team will know which 
substance your child is given. 
 
Pentoxifylline is a medicine that has been shown to decrease the body’s response to 
infection. Specifically, PTX reduces the level of substances (proteins) that allow cells that 
help to fight infection to communicate with each other. These cells that help to fight 
infection, called the inflammatory system, can also be harmful to the body when they are 
over-active. Pentoxifylline can help balance the helpful and harmful aspects of the 
inflammatory response. Your child could also be randomly selected (like flipping a coin) 
to receive placebo (like a “sugar pill” or “sugar water”). The placebo we will give is 
normal saline, which is one of the possible fluids given to your child when his/her blood 
pressure is low. Normal saline is not currently known to influence the way your child’s 
body responds to infection. The study will not require you or your child to do anything 
else after 6 days of receiving either PTX or placebo in addition to antibiotics. 
 
Since there is not conclusive evidence about whether PTX can help children with sepsis 
recover and be discharged from the NICU more quickly than children with sepsis not 
given PTX, there is the same chance of benefit or harm whether your child is given PTX 
or placebo. The purpose of this study is to determine whether PTX can help children with 
sepsis be discharged from the NICU more quickly. The doctor in charge of your child’s 
medical team will determine when your child is ready to be discharged from the NICU. 
The research staff will have no influence over the timing of your child’s discharge from 
the NICU. We will look at your child’s medical chart to determine the number of days 
he/she is cared for in the NICU, and also to determine whether he/she experiences 
medical problems that other children in the NICU sometimes experience. 
 
A group of experts who are not part of the research team will monitor medical 
information about all children involved in the study. You will be told of any significant 
new findings that develop during the course of your child’s participation in this study that 
may affect your willingness to continue to participate. 
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Risks and Inconveniences 
We estimate that the risks of the present protocol to the patient are minimal. Prior studies 
among children given PTX did not report problems with irritability or vital signs, such as 
temperature, heart rate, breathing rate, and blood pressure. However, participation in this 
study may involve risks that are currently not known. Your child will be monitored per 
standard practice in the NICU. The medical team will be in charge of your child’s care 
and will treat any problems, such as with your child’s brain, eyes, heart, lungs, kidneys, 
and stomach or intestines, as they would if your child was not involved in the study. The 
study protocol allows your child to receive antibiotics for the same duration of time your 
child would if he/she was not in the study, and also allows your child to be transferred or 
discharged from the NICU according to the advise of the physician in charge of the 
medical team.    
 
Potential Benefits 
We hope that the knowledge gained by your child’s participation in this study may 
eventually lead to a better treatment of sepsis in infants, as well as a shorter required 
NICU stay for infants with sepsis.  Your child’s participation in this study may help 
physicians manage patients with infection better in the future. 
 
Alternatives 
Pentoxifylline is not part of routine care by which infants with sepsis are currently 
managed. You have the option of deciding whether your child may or may not participate 
in the study. If you choose not to participate in the study, it will not affect your child’s 
care at Yale-New Haven Hospital Children’s Hospital, Bridgeport Hospital, Lawrence 
and Memorial Hospital, Hartford Hospital, or University of Connecticut Health Center, 
either now or in the future. 
 
Economic Considerations 
No payment will be provided for participation in this study. All costs associated with 
your child’s hospitalization and treatment for his/her neonatal condition will be billed to 
you or your insurance company, as would be done if your child were not participating in 
this study.  
 
Confidentiality and Privacy 
All identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
State law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. When the results of the 
research are published or discussed in conferences, no information will be included that 
would reveal your child’s identity unless your specific permission for this activity is 
obtained. No public disclosure of this information will be made. 
 
We understand that information about your child obtained in connection with their health 
is personal, and we are committed to protecting the privacy of that information. If you 
decide to allow your child to be in this study, the researcher will get information that 
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identifies your child and his or her personal health information. This may include 
information that might directly identify your child, such as his or her name, date of birth, 
and medical record number. This information will be de-identified at the earliest reasonable 
time after we receive it, meaning we will replace your child’s identifying information with 
a code that does not directly identify him or her. The principal investigator will keep a link 
that identifies your child to his or her coded information, and this link will be kept secure 
and available only to the principal investigator or selected members of the research team. 
Any information that can identify your child will remain confidential. This information 
will be maintained in a password-protected file on a password-protected computer. All 
copies of this consent form will be maintained in a locked file cabinet. There will be 
nothing in your child’s hospital record that shows his/her participation in this study. The 
research team will only give this coded information to others to carry out this research 
study. The link to your child’s personal information will be kept until the study data is 
analyzed, after which time the link will be destroyed and the data will become anonymous. 
The data will be kept in this anonymous form indefinitely. The information about your 
child’s health that will be collected in this study includes: 
 
• Research study records. 
• Medical and laboratory records of only those services provided in connection with 
this Study.   
• The entire research record and any medical records held by Yale-New Haven 
Hospital Children’s Hospital, Bridgeport Hospital, Lawrence and Memorial 
Hospital, Hartford Hospital, or University of Connecticut Health Center created 
from his/her birth through participation in this study. 
• Maternal health records including demographic and pregnancy/delivery details will 
be collected.   
 
Information about your child and your child’s health which might identify your child may 
be used by or given to:  
• The U.S. Department of Health and Human Services (DHHS) agencies. 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Yale Human Investigation Committee (the committee that 
reviews, approves, and monitors research on human subjects), who are 
responsible for ensuring research compliance. These individuals are required to 
keep all information confidential. 
• Those providers who are participants in the Electronic Medical Record (EMR) 
system. 
• Those individuals at Yale who are responsible for the financial oversight of 
research including billings and payments. 
• The Principal Investigators (Philip J. Yinger and Dr. Lindsay C. Johnston). 
• Governmental agencies to which certain diseases (reportable diseases) must be 
reported. 
• Health care providers who provide services to your child in connection with this 
study. 
• Laboratories and other individuals and organizations that analyze your child’s 
health information in connection with this study, according to the study plan. 
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• Co-Investigators and other investigators. 
• Study Coordinator and Members of the Research Team. 
• Data and Safety Monitoring Boards and others authorized to monitor the 
conduct of the Study. 
• Others as noted: Independent adjudication committee to confirm the duration 
your child spent in the NICU and to confirm other health problems sometimes 
experienced by children in the NICU; independent pharmacist to dispense either 
PTX or placebo. 
 
By signing this form, you authorize the use and/or disclosure of the information described 
above for this research study. The purpose for the uses and disclosures you are authorizing 
is to ensure that the information relating to this research is available to all parties who may 
need it for research purposes. 
 
All health care providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your and your child’s 
information. The research staff at the Yale School of Medicine, Yale-New Haven Hospital, 
Bridgeport Hospital, Lawrence and Memorial Hospital, Hartford Hospital, and University 
of Connecticut Health Center are required to comply with HIPAA and to ensure the 
confidentiality of your and your child’s information in ways not mentioned in this form. 
However, to better protect your child’s health information, agreements are in place with 
these individuals and/or companies that require that they keep your child’s information 
confidential.  
 
You have the right to review and copy your child’s health information in your child’s 
medical record in accordance with institutional medical records policies. There will be 
nothing in your child’s hospital record that shows his/her participation in this study. We 
will keep a copy of this parental consent form, and we will provide you with a copy for 
your records. If in the future you desire any information about the outcome of this 
research, you can contact us and we will be more than willing to provide you with a 
summary of the results. 
 
The results of the research will not be recorded in the infant’s medical record, nor will 
the results be reported back to the parents or the infant’s physician and will have no 
impact on care.  
 
In Case of Injury 
If your child is injured as a result of his or her participation in this study, treatment will 
be provided. Yale School of Medicine, Yale-New Haven Hospital, Bridgeport Hospital, 
Lawrence and Memorial Hospital, Hartford Hospital, and University of Connecticut 
Health Center do not provide funds for the treatment of research-related injury. You or 
your insurance carrier will be expected to pay for the costs of this treatment. No 
additional financial compensation for injury or lost wages is available. You and your 




Voluntary Participation and Withdrawal 
Your child’s participation in this study is completely voluntary. You can decide not to 
participate or withdraw from the study at any time during its course. If you choose not to 
participate or withdraw from the study, it will not affect your child’s medical care, the 
payment for your child’s health care, or your child’s health care benefits at Yale-New 
Haven Hospital, Bridgeport Hospital, Lawrence and Memorial Hospital, Hartford 
Hospital, or University of Connecticut Health Center either now or in the future. 
However, you will not be able to enroll your child in this research study and your child 
will not receive study procedures as a study participant if you do not allow use of your 
child’s information as part of this study.  
 
If you do allow your child to become a participant, you are free to stop and withdraw 
from this study at any time during its course. To withdraw from the study, you can call a 
member of the research team at any time and tell them that your child no longer wants to 
take part. When you withdraw your child’s permission, no new health information 
identifying your child will be gathered after that date. Information that has already been 
gathered may still be used and given to others until the end of the research study, as 
necessary to insure the integrity of the study and/or study oversight. 
 
The authorization to use and disclose your and your child’s information will never expire 
unless and until you change your mind and revoke it. 
 
The study doctors may decide to remove your child from the study if they believe that it 
is in his/her best interests. If you choose not to allow your child to participate or if you 
withdraw your child, it will not harm your relationship with your own doctors or with 
Yale-New Haven Hospital, Bridgeport Hospital, Lawrence and Memorial Hospital, 
Hartford Hospital, or University of Connecticut Health Center. Withdrawing from the 
study will involve no penalty or loss of benefits to which your child is otherwise entitled. 
 
Questions 
We have used some technical terms in this form.  Please feel free to ask about anything 
you don't understand and to consider this research and the permission form carefully – for 
as long as you feel is necessary – before you make a decision. If you have any questions, 














Authorization and Permission 
I have read this form (or someone has read it to me) and have decided to allow my child to 
participate in the project described above. Its general purposes, the particulars of my child’s 
involvement and possible hazards and inconveniences have been explained to my 
satisfaction. My signature also indicates that I have received a copy of this permission 
form. I understand that my participation is voluntary and that I can withdraw my child from 
the study at any time without prejudice. I have read the above and agree to enter this 
research study. Signing this form does not waive any of my legal rights. By signing this 
form, I give permission to the researchers to use and give out information about my child 
for the purposes described in this form. By refusing to give permission, I understand that 
my child will not be able to be in this research.  
 
Name of Subject: _____________________ Name of Subject: _____________________
 
      
                                                       
 
Relationship: ________________________  Relationship: ________________________ 
 
Signature: __________________________   Signature: __________________________ 
 
Date: ______________________________   Date: ______________________________ 
   
___________________________________  ___________________________________ 
Signature of Person Obtaining Permission      Date 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator [Philip J. Yinger, PA-SII at (xxx) xxx-xxxx]. 
 
If after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at (203) 432-5919. 
 
If you would like to talk with someone other than the researchers to discuss problems, 
concerns, and questions you may have concerning this research, or to discuss your rights 
as a research subject, you may contact the Yale Human Investigation Committee at (203) 
785-4688. 
 
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX 
HAS BEEN COMPLETED IN THE HIC OFFICE 
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Appendix D: Baseline Characteristics 
Baseline Characteristics 
Maternal characteristics and intrapartum variables 
• Maternal age (years) 
• Race/ethnicity (free text) 
• Marital status (single/married) 
• Level of education (less than high school, high school graduate, post-secondary 
graduate) 
• Mother’s primary health insurance (public, private, unknown) 
• Prenatal care (Y/N) 
• Location of birth (inborn/outborn) 
• Multiple gestation (singleton/multiple) 
• Chronic hypertension (Y/N) 
• Hypertensive disease of pregnancy (Y/N) 
• Established diabetes (Y/N) 
• Gestational diabetes (Y/N) 
• Unspecified fever > 38.3°C (Y/N) 
• Chorioamnionitis (Y/N) 
• Group B Streptococcus colonization status (colonized/not colonized) 
• Antenatal antibiotic use (Y/N) 
• Antenatal steroid use (Y/N) 
• Oligohydramnios (Y/N) 
• Antenatal hemorrhage (placenta previa or placental abruption) (Y/N) 
• Prolonged rupture of membranes (> 18 hours from membrane rupture to delivery) 
(Y/N) 
• Antenatal fetal distress (Y/N) 
Delivery room variables 
• Delivery mode (Vaginal vertex, vaginal breech, cesarean section) 
• 1-minute Apgar score (0-10) 
• 5-minute Apgar score (0-10) 
• 10-minute Apgar score (0-10) 
• Positive pressure ventilation (Y/N) 
• Endotracheal intubation (Y/N) 
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• Chest compressions (Y/N) 
• Drugs for resuscitation (Y/N) 
Infant characteristics 
• Birth year (free text) 
• Gender (M/F) 
• Gender-specific birth weight percentile (percentile) 
• Gestational age (completed weeks) 
• Birth weight (grams) 
• Small for gestational age (birth weight < 10th percentile for gestational age) (Y/N) 
Comorbidities 
• Accompanying focal infections (lungs, urinary tract, skin, other) 
• Intraventricular hemorrhage (grade I/II) (Y/N) 
• Periventricular leukomalacia (Y/N) 
• Necrotizing enterocolitis (Y/N) 
• Respiratory distress syndrome (Y/N) 
• Therapeutic surfactant (number of doses) 
• Bronchopulmonary dysplasia (Y/N) 
• Retinopathy of prematurity (Y/N) 
• Hydrocephalus (Y/N) 
• Meconium aspiration syndrome (Y/N) 
• Pneumothorax (Y/N) 
• Required treatment for patent ductus arteriosus (Y/N) 
• Inborn errors of metabolism (Y/N) 
• Inguinal hernia (Y/N) 
Clinical variables 
• Mental status change (lethargy, hypotonia) (Y/N) 
• Severe apnea (any single episode requiring positive pressure 
ventilation)/bradycardia (heart rate < 100 beats/min) (Y/N) 
• Abdominal distension/feeding intolerance (Y/N) 
• Hypotension/symptoms of shock (Y/N) 
• Indwelling Foley catheter (Y/N) 
• Central venous catheter (Y/N) 
• Total parenteral nutrition/intralipid solution (Y/N) 
• H2 blockers (Y/N) 
• Postnatal steroids (Y/N) 
• Endotracheal intubation (Y/N) 
• Duration of any respiratory support (supplemental oxygen from 6 hours to at least 
24 hours of age; mechanical ventilation and/or continuous positive airway pressure 
at 24 hours of age; conventional or high-frequency ventilation at any time during 
hospitalization) (days) 
• Cardiovascular support (volume resuscitation or inotropes) (Y/N) 
• Prior treatment with another phosphodiesterase inhibitor or anticoagulants (Y/N) 
• Received breast milk at any time during NICU stay (Y/N) 
• Time to reach full feeds (days) 
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Laboratory variables 
• Hypoproteinemia (Y/N) 
• Glucose instability (Y/N) 
• Leukocytosis/leukopenia (Y/N) 
• Direct hyperbilirubinemia (Y/N) 
• Indirect hyperbilirubinemia (Y/N) 
• Metabolic acidosis (Y/N) 
Sepsis-related variables 
• Timing of disease onset (early-onset/late-onset) 
• Temperature instability in the 24 hours preceding sepsis evaluation (Y/N) 
• Glucose instability in the 24 hours preceding sepsis evaluation (Y/N) 
• Neutrophil abnormalities (neutropenia) at the time the blood culture was obtained 
(Y/N) 
• Platelet abnormalities (thrombocytopenia) at the time the blood culture was 
obtained (Y/N) 
• Duration of antibiotic exposure prior to positive blood culture (days) 
• Age at sepsis evaluation (days) 
• Corrected gestational age at sepsis evaluation (weeks) 
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